Biotechnology

GT Biopharma

GT Biopharma's 1st Phase Clinical Trial for Blood Cancers Shows Promising Results

Jonathan Aschoff Maintains Buy Rating on GT Biopharma

GT Biopharma released FY2025 9 Months earnings on November 14 (EST), actual revenue USD 0, actual EPS USD -1.7053

GT Biopharma released FY2025 Q3 earnings on November 14 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.8267 (forecast USD -0.38)

GT Biopharma completes first phase trial for cancer drug

GT Biopharma released FY2025 Semi-Annual earnings on August 14 (EST), actual revenue USD 0, actual EPS USD -0.8962

GT Biopharma released FY2025 Q2 earnings on August 14 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.55 (forecast USD -0.68)

GT Biopharma Modifies Share Purchase Agreement, Changes Board Members

GT Biopharma's GTB-3650 Trial Advances in Blood Cancer Treatment

GT Biopharma Inc reports improved Q1 EPS loss

GT Biopharma released FY2025 Q1 earnings on May 15 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.3309 (forecast USD -0.64)

GT Biopharma Inc Expected to Report a Loss of 64 Cents Per Share

GT Biopharma Inc reports Q1 2025 loss forecast and maintains buy rating

GT Biopharma released FY2024 Annual Earnings on February 21 (EST), actual revenue 0 USD (forecast 0 USD), actual EPS -6.9369 USD (forecast -6.79 USD)

GT Biopharma released FY2024 Q4 earnings on February 21 (EST), actual revenue 0 USD (forecast 0 USD), actual EPS -1.6721 USD (forecast -1.55 USD)

GT Biopharma Administers First Dose of GTB-3650

GT Biopharma released FY2024 Q3 earnings on November 14 (EST), actual revenue 0 USD (forecast 0 USD), actual EPS -1.5266 USD (forecast -2.7 USD)

GT Biopharma released FY2024 Cumulative 3Q Earnings on November 14, 2024 (EST), with Revenue at 0 and EPS at -5.335

GT Biopharma's GTB-3650 Receives FDA Approval for Clinical Trials

GT Biopharma released FY2023 Cumulative 3Q Earnings on November 1, 2023 (EST), with Revenue at 0 and EPS at -3.4643

Starfighters Space

Aimei Health Tech

T-Rex 2X Long DJT Daily Target ETF

Athira Pharma

Sable Offshore

Zeta Network

Vivakor

Trump Media & Tech

Safe and Green Development

VS MEDIA

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap